Retina-Vitreous Associates Medical Group   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 4
Founded: Los Angeles CA United States

Organization Overview

First Clinical Trial
2013
NCT01946399
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Retina-Vitreous Associates Medical Group | Retina-Vitreous Associates Medical Group, Los Angeles CA

Active Ingredients

Drugs in Phase 4 Trials (1)

aflibercept (zaltrap) (1 trial)

Drugs in Phase 2 Trials (1)

human retinal progenitor cells (1 trial)

Drugs in Phase 1 Trials (2)

kvd001 (1 trial)

neural progenitor cell (1 trial)

Drugs in Other Trials (2)

dexamethasone (1 trial)

loteprednol (lotemax) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Edema (Phase 4)

Macular Edema (Phase 4)

Retinitis (Phase 2)

Retinitis Pigmentosa (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 6